$218.3M
+$218.3M this year1 filing since 2026 · latest Equity filed
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of lead-212 (212Pb)-based targeted alpha therapies for cancer, including prostate, breast, and lung cancer. Its platform addresses the industry's biggest constraint, reliable and scalable isotope supply, with proprietary 212Pb production technology and manufacturing facilities. In July 2026 it closed an oversubscribed US$315 million Series D led by Ally Bridge Group to take its lead prostate cancer program, ADVC001, into Phase III and to expand clinical and commercial manufacturing, including a 128,000-square-foot US hub in Andover, Massachusetts. The company, founded in Australia in 2019, also has a strategic collaboration with Eli Lilly on novel targeted alpha therapies.
What sets it apart
Vertically integrated 212Pb isotope production that gives it daily access to the alpha-emitting isotope, solving the supply bottleneck that constrains targeted alpha therapy development at scale.
A 212Pb-based targeted alpha therapy for prostate cancer, advancing toward Phase III development on the back of the 2026 Series D financing.
